BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
- Conditions
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 50
- Registration Number
- NCT05348876
- Locations
- 🇮🇳
Victoria Hospital, Bangalore, Punjab, India
🇮🇳Sujan Surgical Cancer Hospital & Amravati Cancer Foundation, Amravati, Maharashtra, India
🇮🇳Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, Uttar Pradesh, India
A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
- Conditions
- Interventions
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 8
- Registration Number
- NCT05301062
- Locations
- 🇨🇳
Many locations, Multiple Locations, China
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 807
- Registration Number
- NCT05254002
- Locations
- 🇺🇸
Healor Primary Care / CCT Research, Las Vegas, Nevada, United States
🇺🇸Santa Rosa Medical Centers of Nevada / CCT Research, Las Vegas, Nevada, United States
🇺🇸Circuit Clinical/Crystal Run, Middletown, New York, United States
A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 93
- Registration Number
- NCT05236257
- Locations
- 🇫🇷
Multiple Locations, Multiple Locations, France
A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain
- Conditions
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 80
- Registration Number
- NCT05219812
- Locations
- 🇩🇪
InnoDiab Forschung GmbH, Essen, Nordrhein-Westfalen, Germany
🇬🇧MAC Research Centre - Manchester, Manchester, United Kingdom
🇩🇪Klinische Forschung Hannover-Mitte GmbH, Hannover, Niedersachsen, Germany
A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 6
- Registration Number
- NCT05217914
- Locations
- 🇨🇳
Many Locations, Multiple Locations, Taiwan
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 13779
- Registration Number
- NCT05202301
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
- Conditions
- Interventions
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 219
- Registration Number
- NCT05196035
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Emory University Hospital/Children's Healthcare of Atlanta (CHOA), Atlanta, Georgia, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice
- Conditions
- Interventions
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 368
- Registration Number
- NCT05192642
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A Study Called Champion-HMB to Learn More About Females With Heavy Menstrual Bleeding and Available Treatments to Enable Earlier Diagnosis and to Predict Courses of Treatment
- Conditions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 99999
- Registration Number
- NCT05176496
- Locations
- 🇩🇪
Bayer, Berlin, Germany